UK biotech venture investment reaches five-year high in Q2 2026
UK biotech financing hit a five-year high in the second quarter of 2026, with total equity financing reaching £2.11 billion ($2.84 billion), including a record £2.05 billion in venture capital, according to new figures from the BioIndustry Association (BIA).
The quarter was dominated by Isomorphic Labs’ landmark £1.6 billion Series B round, a major validation of the UK’s global leadership in AI-driven drug discovery. Even excluding this record financing, UK biotech companies secured £498 million in venture capital during Q2 – almost double the £279 million raised in Q2 2025.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze